Efficacy and safety of netakimab therapy in patients with moderate to severe psoriasis in real clinical practice
Rationale. Data from randomized clinical trials (RCTs) may differ from the results of the efficacy and safety of medicines in the conditions of daily work. Purpose. To obtain data on the long-term efficacy and safety of the use of the genetically engineered biological drug netakimab in real clinical...
Saved in:
Main Authors: | Andrey L. Bakulev (Author), Olga A. Pritulo (Author), Zhanna S. Kuntsevich (Author), Alkes A. Khotko (Author), Anastasiya A. Yunovidova (Author), Pavel V. Gorognichev (Author), Oleg R. Ziganshin (Author), Natalya S. Rudneva (Author), Evgeniya V. Bildyuk (Author), Tatiana V. Repina (Author), Valentina Y. Dudko (Author), Mariya D. Maksimova (Author) |
---|---|
Format: | Book |
Published: |
State Scientific Center of Dermatovenereology and Cosmetology,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext
by: A. L. Bakulev, et al.
Published: (2019) -
Netakimab - new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis
by: A. A. Kubanov, et al.
Published: (2019) -
Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial
by: Luis Puig, et al.
Published: (2021) -
Profiles of patients with psoriasis for appointment gene-engineering biological therapy - clinical justification
by: Alexander S. Zhukov, et al.
Published: (2020) -
Efficacy and safety profile of 2-year netakimab treatment in patients with moderate-to-severe plaque psoriasis in terms of the randomized double-blind placebo-controlled BCD-085-7/PLANETA clinical trial
by: Andrey I. Bakulev, et al.
Published: (2022)